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Abstract 
 
Conjugated Bile Acid and Sphingosine 1-phosophate Prompt Cholangiocarcinoma Cell 
Growth via Releasing Exosomes 
 
 
By Waad Alruwaili, MSc. 
 
 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
at Virginia Commonwealth University 
Virginia Commonwealth University, 2019  
 
Major Director: Huiping Zhou, Professor, Department of Microbiology and Immunology 
 
Cholangiocarcinoma (CCA) is a fatal primary malignancy that is formed in the bile ducts. 
Cancer-associated myofibroblasts play a crucial role in CCA proliferation and invasion. 
Furthermore, there is a growing interest in the role of the exosome in the interaction between the 
cancer-associated myofibroblasts and cholangiocarcinoma which lead to CCA growth. However 
how cholangiocarcinoma-derived exosome affect the cancer-associated myofibroblasts in the 
tumor microenvironment remain unknown. In this study, we examined whether exosome 
produced by cholangiocarcinoma could involve in the prompt of CCA cells growth by regulation 
of myofibroblast. We found that cholangiocarcinoma-derived exosome could prompt elevated α-
smooth muscle actin and stromal cell-derived factor one expression that induces myofibroblast 
proliferation. We then demonstrated that cholangiocarcinoma-derived exosome upregulated 
periostin expression that plays an important role in cancer metastasis. In 3D organotypic rat CCA 
coculture model, TCA and S1P considerably increase the growth of CCA cell. Conclusion: 
cholangiocarcinoma-derived exosome trigger cancer-associated myofibroblasts proliferation in 
the tumor microenvironment that leads to prompt CCA growth. 
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Chapter: 1 Introduction 
 
1.1 Cancer Biology 
 
Cancer is characterized by uncontrolled cell growth and proliferation. Cancer cells grow 
and divide out control and spread and destroy normal body tissue. In addition, cancer cells 
acquire new features, including alterations in cell structure, size, cell adhesion properties, 
replication time, and the production of new enzymes. Cancers are generally classified according 
to the organ in which they originate, and there are more than 100 types of cancer. Although cancer 
is an extremely complicated and highly diverse disease with multiple types, a group of features 
are common among nearly all malignancies. Those characteristics are called cancer hallmarks. 
These hallmarks represent molecular and biochemical changes in cells that are common in most 
cancer types and are acquired to change a normal cell into a malignant cell 1 (Fig. 1). 
A tumor can be defined as non-cancerous (benign) or malignant based on its growth and 
behavior. Benign tumors grow slowly, do not invade nearby tissues and are not life-threatening 
unless they interrupt the function of an organ or tissue. However, in malignant, cells can spread 
from where they first formed (primary cancer) to a new location in the body through blood 
circulation or lymph vessels to form new tumors in other areas of the body.  
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Figure 1. Diagrammatic Representation of the Hallmarks of Cancer. This diagram illustrates 
the six hallmarks of cancer through different mechanisms 2. This image was adapted from 
Hanahan et al. 2011.  
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Figure 1 Diagrammatic Representation of The Hallmarks of Cancer. 
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1.1.1 Causes and Risk Factors of Cancer 
Cancer is a complicated group of diseases that can be associated with several causes. At its 
core, cancer is caused by changes (mutations) to the DNA within cells. This mutation directs the 
cell to grow and divide more rapidly. Behaviors such as smoking, excess alcohol consumption, 
overexposure to ultraviolet (UV) light from the sun, unhealthy diet choices, obesity, and physical 
inactivity can lead to cancer. Furthermore, a handful of viruses may play a role in cancer 
development. For instance, hepatitis B infection can lead to hepatocellular carcinoma 3, Epstein-
Barr infection is linked to various types of cancer 4 and human papillomavirus is the primary 
cause of cervical cancer 5. However, it is not yet completely understood how many mutations 
must accumulate for cancer to occur. 
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1.2 Cholangiocarcinoma 
Cholangiocarcinoma (CCA), or bile duct carcinoma arising from the cholangiocytes, which 
form a network of ducts responsible for the transport of bile acid and the production of 
bicarbonate lining the biliary tree. CCA is the second most common primary liver malignancy 
after hepatocellular carcinoma (HCC) and the most common biliary tract malignancy. Based on 
the anatomical localization, CCA tumors are classified into intrahepatic (ICCA), which are 
defined as a CCA located in bile ducts inside the liver; distal (dCCA), which are limited to the 
region between the origin of the cystic duct and ampulla of Vater and perihilar; and perihilar 
(pCCA), which are found in the area between the right and left bile ducts leaving the liver and 
connect to form the common hepatic duct, as shown in (Figure 2) However, this classification 
does not show the distinctive biological properties  of CCA 6. Most CCA tumors are in the 
perihilar and distal region, while ICC represents roughly 8–10% of all CCAs  7. 
 
 
 
 
 
 
 
 
 
 
 
  
6 
 
 
 
 
 
 
 
Figure 2. CCA classification. CCA is classified based on its anatomical location inside the 
biliary tree into intrahepatic(iCCA), perihilar (pCCA), and distal (dCCA) 
Cholangiocarcinoma8 This image was adapted from Blechacz. 2017.  
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Figure 2 CCA classification 
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1.2.1 Epidemiology 
An increasing number of studies have reported that the incidence and mortality of CCA have 
increased worldwide. For instance, in the United States, the CCA incidence rate increased 165% 
in 30 years to 0.95 cases per 100,0009,10. In addition, in the last decade, the CCA incidence has 
increased and the mortality rates were 9% greater in Europe 11. The highest reported CCA 
prevalence was in northeast Thailand (85/100,000) and it is around 85% of the total primitive 
liver cancers 12, demonstrating a distinct variation in its geographical distribution (Figure 3). 
CCA symptoms do not develop until cancer has reached a more serious stage, and the clinical 
diagnosis is challenging because it is clinically silent in the patient and largely shows non-
specific symptoms 13. Furthermore, a substantial problem encountered with CCA is that it is 
usually diagnosed when intrahepatic or lymph node metastasis has already occurred and the only 
potentially curative treatment existing is surgical resection. However, the 5-year survival rate 
after surgery is less than 45%, and recurrence rates are very high (49%–64%)  14. 
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Figure 3. Worldwide incidence of CCA. This map illustrates the incidence of CCA from 
1971-2009. Pink color shows countries with higher incidence, while green color show 
countries with a low incidence 15. This image was adapted from Banales et al., 2016.  
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Figure 3Worldwide incidence of CCA 
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1.2.2 Risk factors 
CCA development is usually not associated with a known risk factor, and CCA can grow in a 
noncirrhotic liver 16. However, numerous established risk factors predispose to CCA, and the 
geographical distribution of CCA reflects the prevalence of its risk factors. Risk factors can 
include infection with hepatobiliary flukes, primary sclerosing cholangitis, and biliary duct cysts. 
Additionally, other risks factors are currently being studied such as smoking, obesity and 
diabetes mellitus.  
1.2.2.1 Liver flukes 
The hepatobiliary flukes Opisthorchis viverrini (O. viverrini) and Clonorchis sinensis (C. 
sinensis) are well-established CCA risk factors. Humans are infected with these flukes through 
the consumption of raw or undercooked foods (salted, pickled, or smoked). Both species have 
similar life cycles and are small flatworms that mature in the biliary duct system. Eggs produced 
by adult worms pass down the bile duct and exit in the feces. If the eggs reach a freshwater body, 
they can be swallowed by snails, which are the primary intermediate host, where they hatch and 
then develop into cercariae and then enter the flesh of freshwater fish, the secondary intermediate 
host, where they mature into metacercariae.  
 Chronic infection with O. viverrini and C. sinensis  and persistent inflammation are crucial 
factors in human cancer development 17. This scenario leads to biliary duct ulceration and 
chronic inflammation, which induce oxidative and nitrative tissue and DNA damage; these could 
be driving forces that lead to cholangiocarcinogenesis 18.   
 The development of CCA is geographically associated with the liver fluke, particularly in the 
East Asia. Opisthorchis viverrini is endemic in several regions such as northeast Thailand, Laos, 
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and Cambodia, whereas Clonorchis sinensis is common in Korea, China, Taiwan and Vietnam 
19. 
1.2.2.2 Primary sclerosing cholangitis 
Primary sclerosing cholangitis (PSC) is an autoimmune disease that is characterized by 
chronic inflammation resulting from strictures and stenosis (narrowing) of extrahepatic and/or 
intrahepatic bile ducts. The majority of patients do not show any symptoms. Fatigue and upper 
abdominal discomfort are common symptoms. In advance stages, patients can develop pruritus 
and jaundice due to cholestasis. 
PSC is associated with the development of CCA. Chronic inflammation and the 
proliferation of progenitor cells are postulated mechanisms of CCA formation 7. Patients 
diagnosed with PSC have been reported to have a lifetime prevalence of CCA ranging between 
5% and 10%, and approximately half of the patients with CCA are diagnosed within 26 months 
following a diagnosis of PSC 20. 
1.2.2.3 Biliary stones 
  Biliary stones have been associated with an increased risk of CCA. Most biliary stones 
are found in the gallbladder. However, they can occasionally cross the cystic duct to the 
intrahepatic bile ducts proximal to the right and left hepatic duct and lead to hepatolithiasis. They 
can also proceed to the extrahepatic bile ducts and cause a condition called choledocholithiasis. 
Furthermore, an estimated 7% of patients who have hepatolithiasis progress to intrahepatic CCA 
7. 
The incidence of hepatolithiasis is low in Western countries but is a more common risk 
factor in numerous Asian countries where the incidence ranges from 2% to 25% 21. 
Hepatolithiasis is a well-known risk factor for ICC. 
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1.2.2.4 Biliary Tract Disorders 
Choledochal cysts are rare congenital dilatations of the extrahepatic and intrahepatic bile 
ducts and can be single or multiple. Ductal dilation occurs when pancreatic enzymes reflux into 
the biliary system following increased intraductal pressure and inflammation. Numerous 
hepatobiliary complications are associated with bile duct cysts such as cirrhosis, pancreatitis, 
cholelithiasis, and pancreatic duct obstruction. Bile duct cysts are also an established risk factor 
for CCA. Pancreatic enzymes reflux, cholestasis, and elevated bile acid concentrations have been 
postulated to further prompt malignant formation in patients with choledochal cysts 22. 
The prevalence of CCA in Asians with bile duct cysts is approximately 18%, which is 
higher than that in the United States where the incidence is approximately 6% 23. Complete 
choledochal cyst removal can lower the risk of cancer, but choledochal cysts patients continue to 
have a greater chance of developing CCA than people who do not have choledochal cysts 23. 
1.2.2.5 Chemical carcinogens 
  Exposure to certain chemicals has been strongly associated with an increased risk of 
developing CCA. These include dioxin, asbestos, radon, and thorium dioxide, commercially 
labeled as Thorotrast 9. Thorotrast is a radiographic contrast agent that was used worldwide from 
1930 to 1950 as an intravascular contrast agent but was banned in 1960. Thorotrast exposure is 
strongly associated with a 300-fold increased risk of developing CCA 9, and the average latency 
period associated with Thorotrast is 16-45 years after exposure. Thorotrast can deposit in the 
reticuloendothelial system involving the spleen, liver, bone marrow and, lymph nodes 24. 
Nevertheless, the association between radiation exposure and hepatobiliary malignancy has not 
been fully established. 
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1.2.2.6 Possible Risk Factors 
A number of additional factors have been suggested to influence the risk of developing 
cholangiocarcinoma. More specifically, chronic viral hepatitis and cirrhosis are associated with 
CCA. An increasing number of studies have found that hepatitis C can be a contributing factor to 
iCCA 25. Additionally, diabetes, obesity, tobacco smoking, and alcoholic liver disease have been 
implicated in CCA 23. Despite the well-established association between the risk factors and CCA, 
the majority of patients develop CCA in the absence of identifiable risk factors. 
1.2.3 Tumor phenotypes 
CCA presents very heterogeneous malignancies from morphological, histological, and 
biological standpoints. Classically, CCA has been divided into intrahepatic, perihilar and distal 
CCA. However, these are also classified based on their macroscopic growth pattern into mass-
forming, periductal-infiltrating or intraductal-papillary as illustrated in (Figure 4). In addition, 
CCAs can exist as a single or mixed growth form. The masses located in the liver parenchyma 
enter the hepatic parenchyma through the portal venous system and invade lymphatic vessels at 
advanced stages. This represents the most common growth type 13. The periductal-infiltrating 
type primarily extends along and within the bile duct. Furthermore, Histologically, 90%-95% of 
CCA are adenocarcinomas.The tumors show grades of differentiation (poor to moderate) with 
greatly desmoplastic stroma and distinct mucin expression 8. 
Although CCA originates from transformed biliary epithelial cells (cholangiocytes), 
hepatic progenitor cells (HPCs) have been suggested to also represent the cell of origin 26. 
Tumorigenesis in CCA is a complex multistep process involving conversion from hyperplasia to 
dysplasia and finally to carcinoma. Chronic inflammation and partial blocking of bile flow cause 
chronic cholestasis and prolonged biliary cell exposure to the carcinogenetic elements in bile that 
  
15 
are associated with bile duct obstruction (BDO). Nevertheless, the specific mechanisms of how 
bile acid signals may promote CCA and how they are involved in invasive biliary tumor growth 
are not yet completely understood.  
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Figure 4. Classification of CCA Based on Its Gross Morphologic. CCA can be classified into 
three forms of growth: mass-forming, periductal-infiltrating, and intraductal-growth13. 
Illustrations adapted from Blechacz et al., 2011. 
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Figure 4Classification of CCA Based on Its Gross Morphologic. 
 
  
18 
1.3 Metastasis and the tumor microenvironment  
Metastasis is the primary cause of mortality in patients with cancer. Cancer metastasis is the 
spread of tumor cells through the bloodstream or the lymphatic system and eventually forming a 
secondary tumor in other organs or tissues. Importantly,  The majority of CCA-related deaths 
result from the spread of CCA cancer cells to other organs, and it has a poor-outcome due to the 
propensity of cancer cells to metastasize27. 
Although genetic characteristics of the cancer are considered as the leading causes 
driving metastasis, it is also important to understanding how tumor microenvironment (TME) 
influence tumor progression. The TME involves of extracellular matrix (ECM), immune cells 
and fibroblasts.   
Each component of the TME has a specific function in inducing cancer initiation, 
progression, invasion, and metastasis. Many TME components have been well-known to play a 
role in metastasis, but continuous activation of myofibroblasts plays a significant role in 
metastasis. In addition, myofibroblasts  is the most prevalent component in CCA tumor 
microenvironment 28.  
Furthermore, the interaction between the cancer cells and myofibroblasts has a critical 
role in tumor development and metastasis. Yet, the mechanisms responsible for this inter-cellular 
communication are not widely understood so a component that is vital to our understanding is 
how the inter-cellular communication occurs between tumor cells and myofibroblasts that lead to 
CCA progression and metastasis. Cell–microenvironment interaction mediated by secreted 
vesicles termed exosomes is widely considered 29. However, given that the role of exosomes 
during CCA metastasis is not elucidated, and the mechanism by which exosomes affect 
fibroblast remains vague. Thus, it is important to find if the exosomes mediated the 
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communication between tumor cells and myofibroblasts to promote cancer development and 
metastasis in CCA. 
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1.4 Bile Acid 
 
1.4.1 Synthesis and Conjugation: 
Bile acids are detergent molecules synthesized from cholesterol in a multistep process. Bile 
acids are amphipathic steroid molecules that can serve as powerful detergents for the absorption 
of lipids and fat-soluble vitamins in the intestine. Bile acids are synthesized from cholesterol in 
the liver through two pathways, the classical or neutral pathway and the alternative or acidic 
pathway. Both pathways produce the primary bile acids cholic acid (CA) and chenodeoxycholic 
acid (CDCA). In humans, the classical pathway is the primary source of bile acid biosynthesis 
and accounts for approximately 90% of total bile acids. The classic pathway involves the 
hydroxylation of cholesterol at the 7 position via ER enzyme cholesterol 7α-hydroxylase 
(CYP7A1) and produces 7- hydroxycholesterol in the rate-limiting step in the reaction to yield 
two primary bile acids, CA and CDCA, in the liver. A 12α-hydroxylase is necessary to catalyze 
CA synthesis, and without CYP8B1, CDCA synthesis will occur. There is also an “acidic 
pathway” or alternative pathway that initiates the hydroxylation of cholesterol at the 27 position 
by the mitochondrial enzyme sterol 27-hydroxylase to yield chenodeoxycholic acid. 
Primary bile acids that are formed in the liver from cholesterol are further converted by gut 
bacteria to secondary bile acid deoxycholic acid (DCA  ( and lithocholic acid (LCA) from CA and 
CDCA, respectively. Before being released into the biliary tree, these bile acids are conjugated 
with the amino acid taurine or glycine. Cholic acid and chenodeoxycholic acid are conjugated 
with glycine to synthesis glycocholic acid and glycochenodeoxycholic acid or with taurine to 
synthesis taurocholic acid and taurochenodeoxycholic acid. This conjugation increases 
hydrophilicity, which enhances solubility in bile and assists in bile flow. 
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1.5 Exosome 
 Exosomes are the smallest group in the extracellular vesicles. Exosomes are small 
vesicles that are characterized by a size range from 40 nm to 100 nm in diameter and are having 
identical lipid bi-layer membrane from the original cell30. The size of exosomes limits their 
analysis, and they require the use of electron microscopy instead of light microscopy. Exosomes 
contain protein and RNA and have the ability to carry their cargo between cells. Trams et al. first 
described the exosome via electron microscopy (EM) in 1981 as exfoliated vesicles with 
ectoenzyme activity 31. Two years later, Harding and Stahl Show that rat reticulocyte can 
produce small vesicles and tubules 32.     
1.5.1 Exosome origin, biogenesis, and secretion 
Exosomes are a group of heterogeneous vesicles called extracellular vesicles (EVs), which 
are produced and secreted by a multitude of cell types 33. EVs are distinct in terms of size and 
biogenesis, and they include the exosome as well as apoptotic bodies and microvesicles. 
Apoptotic bodies are characteristic membrane blebs measuring 1000-5000 nm in diameter those 
are produced and released by cells undergoing apoptosis. In contrast, microvesicles are 150-1000 
nm and are produced by “pinching off” from the plasma membrane. 
Exosomes are formed in the endocytic tract within the multivesicular body (MVB) 
compartments. This formation occure intracellularly inside the endosomal/lysosomal system, 
which performs functions that are important for intracellular protein transferring between diverse 
organelles and the cell membrane. Exosomes are then released from the cell via exocytosis. 
There are four steps included in exosome biogenesis: initiation, endocytosis, MVBs formation, 
and exosome secretion. 
The endosomal system also includes the exosome biogenesis processing of endocytic 
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vesicles, early endosomes, late endosomes, and lysosomes. The biogenesis of 
exosomes begins in reverse budding, causing the vesicles to carry cytosol and reveal the 
extracellular space of surface receptors34. The exosomes then intrinsically fuse with the plasma 
membrane by Ca++-dependent activation or the activation of Rab-GTPases35. Next, Rab25 
controls exosome binding to and tethering with the plasma membrane and Rab27b exosome 
release36,37. 
1.5.2 The molecular composition of exosomes 
Exosomes are known to have a variety of unique constituent-like lipids, proteins and nucleic 
acids derived from the original cells. A general overview of molecules typically found in 
exosomes is shown in (Figure 5) 
Numerous proteins repeatedly detected in exosomal preparations are considered to be 
exosome markers 38. Such as, tetraspanins (CD81, CD82, CD9, CD63), heat shock proteins, 
membrane transport and fusion proteins (Alix, TSG101).  
Microvesicles contain a wide array of functional RNA involving mRNA and small 
noncoding RNA (miRNA) 39. Functional mRNAs can convey to target cells where they are 
translated into proteins that alter cellular signaling. An increasing number of studies have found 
that different types of cells, for example, dendrite cells, B- and T-lymphocytes, and stomach 
cancer cells, release exosomes that contain RNA 40,41.  
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Figure 5. Typical content of exosome. A schematic diagram of the overall constituents of 
exosome 42. This image was adapted from Hu et al. 2012.  
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Figure 5Typical content of exosome 
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1.5.3 Importance in normal physiology 
 Exosomes are shed by most cell types, circulate in different bodily fluids (e.g., urine, 
blood, and saliva) and move their load to recipient cells. The presence of exosomes in normal 
biological fluids indicates that they are involved in physiological processes. However, the role of 
exosomes in normal physiology depends on their cell/tissue of origin. 
A role for exosomes during pregnancy has been proposed 43. Mitchell et al. showed that 
the human placenta produces exosomes in the maternal circulation at approximately 6–7 weeks 
into gestation. Hence, exosomes could play a vital role in signaling by facilitating 
communication between maternal and fetal circulation during pregnancy. One example of these 
roles is the maternal-fetal tolerance that is crucial during gestation. The placenta-derived 
exosomes impair maternal T-cell signaling and support maternal immune tolerance to the fetus 
44. In addition, the exosome complex has a significant impact on both innate and acquired 
immune system components. For instance, NK cells can produce exosomes that are cytotoxic 
against cancer cells and that stimulate immune cells 45. 
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1.5.4 Systemic effects of tumor-derived exosomes 
Metastasis begins with the dissemination of cells from the primary neoplasm to remote 
organs followed by their uncontrolled growth. In certain metastatic sites, the cross talk between 
primary tumors, stromal constituents, and the immune system is essential for the creation of a 
“premetastatic niche” 46. Exosomes that facilitate cellular communication can be used by tumor 
cells in pre-metastatic niche formation. However, continuing research indicates that exosomes 
play a role in cancer development and progression. Recent studies proposed that cancer cells and 
host-stromal cells are augmented by tumor-derived exosomes to define organ-specific metastasis 
and acquire metastatic phenotypes 47–50. Bone marrow MSC-derived exosomes (MSC-exosomes) 
can upregulated the vascular endothelial growth factor (VEGF) expression in cancer cells that 
promote tumor proliferation 51. Peinado et al. stated that melanoma-derived exosomes support 
metastasis by augmented bone marrow-derived progenitor cells (BMDCs) 49. More recent 
evidence shows that exosomes that are secreted from myofibroblasts promote metastasis in 
breast cancer cells52. Therefore, understanding the role of the exosome in pathogenesis and 
metastasis on the systemic, cellular and molecular levels are vital goals of cancer research.  
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1.6 Aim of the study 
The previous study carried out by our lab shows that conjugated bile acid can induce CCA 
growth and invasion via S1PR253. In addition, knowing that exosome plays a role in cell-cell 
communication and also, the significant influence of the exosome to modify the tumor 
microenvironment, I hypothesized that Sphingosine 1-phosophate prompt CCA cells growth by 
releasing exosome. To examine this hypothesis, I studied the following aims: 
Aim 1: CCA-derived exosome can influence tumor microenvironment. 
1.    Isolation and purification of CCA-derived exosome. 
2.    Demonstrating that CCA cells produce exosome. 
3.    Treatment of CCA associated myofibroblast (TDEsp-TDFE4) with exosome from CCA cells 
(BDEsp-TDEH10) pretreated with Sphingosine 1-phosophate. 
4.    Showing that CCA-derived exosome increases the production of growth factors from the 
myofibroblast. 
Aim 2: CCA-derived exosome mediates the growth of CCA. 
1-    Isolation of exosome following treatment of CCA cells (BDEsp-TDEH10) with Sphingosine 
1-phosophate. 
2-    Establishment of CCA associated myofibroblast (TDEsp-TDFE4) and CCA cells (BDEsp-
TDEH10) in 3D organotypic CA coculture model. 
3-    Evaluate CCA spheroid numbers.  
Aim 3: Sphingosine 1-phosophate influence the content of the CCA-derived exosome. 
1.    Treatment of CCA cells with Sphingosine 1-phosophate. 
2.    Isolation and purification of CCA-derived exosome. 
3.    Evaluation of the exosome content using RT-PCR. 
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2 Chapter 2: Materials and Methods 
 
2.1 Cell lines used in this study 
Two rat CCA cell lines were used in the present study. BDEsp tumor-derived BDEsp-
TDEH10 CCA cell strain (clone H10), and BDEsp tumor-derived BDEsp-TDFE4 cancer-
associated myofibroblastic cell strain. 
2.1.1 Thawing 
Cryovial containing the frozen Cells were removed from liquid nitrogen tank and directly 
thawed in a 37°C water bath for 1 min. The cells were then transferred to a centrifuge tube 
containing a pre-warmed medium suitable for the cells and spun gently at 1350 g for 5 min. The 
cells were then resuspended in medium and transferred into the suitable culture dish. After a 
given time to enable attachment to the surface of the petri dish (overnight), the culture media was 
changed to remove the remaining DMSO. 
2.1.2 Freezing  
Cells were gently detached from the culture dish following the same technique in the the 
subculture and resuspended in a complete growth medium. After counting with a cell counter 
and trypan blue exclusion, the cells were resuspended in culture media with DMSO and 
separated into tubes with one million cells each. To evade fracturing of the cell membrane due to 
rapid freezing, the tubes were placed in a -80°C freezer. The frozen tubes were moved to liquid 
nitrogen tanks for long-term storage. 
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2.1.3 Cell culturing  
Cells were maintained as adherent monolayers in a tissue culture dish in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS), 1% penicillin-
streptomycin solution to prevent bacterial growth, insulin (1 μmol/L) and transferrin (5 μg/mL) 
. For exosome isolation, the DMEM medium was supplemented with fetal bovine serum pre-
depleted with exosomes by ultracentrifugation. myofibroblasts were cultured with the same 
supplements in the DMEM medium. All cells were cultured under sterile conditions at 37°C with 
5% CO2 in humidified cell culture incubators. 
2.1.4 Subculturing  
The cells were consistently propagated as soon as they reached 80-90% confluence. 
Briefly, the cell culture media from the culture dish was removed. Trypsin was then added to 
detach the cells, and the dish was incubated for 3-5 min at 37oC. The cell was then moved to a 
tube with equivalent volumes of pre-warmed complete growth medium. This tube was 
centrifuged at 1350 × g for 5 min. The pellets were resuspended in growth medium. The suitable 
amount was pipetted into new cell culture dishes. 
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2.2 Exosome purification by differential centrifugation   
Exosomes were purified from the supernatant of BDEsp-TDEH10 cell culture media 
following a protocol consisting of three successive series of centrifugation .7 x 106
 
cells were 
plated in a 150 mm Petri dish in DMEM supplemented with .1% FBS. The following day, the 
media were changed to exosome-free DMEM and treated with Taurochenodeoxycholic acid 
(TCA) (100 μM), Sphingosine 1 phosphate (S1P) (100 nM), and deoxycholic acid (DCA) (50 
μM). The cells were grown to 80-85% confluence during the 48-hour culturing period.  
The culture media was centrifuged at low speed at 2000 x g for 15 min at 4°C to clear from 
cell debris. The supernatant was transferred to polypropylene tubes (Beckman Coulter) and 
centrifuged at 16,000 x g for 20 min at 4°C using a WX Ultra 100 from Thermo Fisher Scientific 
(Waltham, MA). The supernatant was then filtered through a 0.22-μm cellulose acetate 
membrane 50 ml filter system (Corning Incorporated), and the media was further centrifuged at 
100000 × g for 90 min to generate the exosome pellet. The exosome pellet was dissolved in 
sterile phosphate-buffered saline (PBS) and stored at -80°C for further use.  
2.3 Western blotting and immunodetection  
2.3.1 Cell lysates  
Confluent cells were washed with cold PBS and scraped from the culture dish. The cell 
was transferrd in a tube and centrifuged at 10000 RPM for 5 min at 4oC. The PBS was discarded, 
and RIPA buffer was added to the cell pellet. The sample was vortexed at 4oC for 2 min and 
centrifuged at 10000 RPM for 5 min at 4oC. The supernatant then was transferred to a new tube. 
Finally, samples were stored at -80°C.  
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2.3.2 Gel electrophoresis  
Based on the Bradford estimate of protein concentrations, 70 μg of protein was loaded on 
a gel. An equal amount of the denatured samples and Precision Plus ProtienTM All Blue Plus 2 
Standard (Bio-Rad) were loaded into the wells of a 10% gel. The gel was inserted into an 
electrophoresis chamber that was loaded with running buffer. The proteins were separated by 
molecular weight at 80 V through the stacking gel and then run at 120 V until the dye front 
reaches the bottom of the gel (approximately 90 min). After separation, the gel was transmitted 
to the blotting device. 
2.3.3 Blotting  
A wet blotting technique was used to move the proteins from the gel to 0.45 µm 
nitrocellulose membranes (Thermo, USA). The pre-run gel that was transmitted on the 
nitrocellulose membrane then inserted between two cassettes. During the transfer, any trapped air 
bubbles were removed by a blotting roller. The sandwich was then immersed in the transfer 
buffer. The device performed the transfer in a closed circuit according to the programmed 
parameters.  
2.3.4 Blocking the membrane  
The membrane was blocked to avoid non-specific binding of the primary and/or 
secondary antibodies to the membrane. Immunoblots were blocked for 1 hour at RT under 
agitation with 5% non-fat milk in TBS buffer to prevent unspecific antibody binding to the 
membrane. Last, the membranes were rinsed for 5 seconds in TBST after incubation.  
2.3.5 Antibody incubation   
Antibodies were used to detect the proteins of interest. The membrane was incubated 
with primary antibody (1:500) diluted in TBST buffer containing 0.1% bovine serum albumin 
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(BSA) overnight at 4°C under agitation. The membrane was washed three times using TBST for 
15 min each to remove excess antibody solution. The membrane was then incubated with a 
secondary antibody (1:2000) for 1 h at room temperature and subsequently washed three times 
for 15 min. The antibodies of western blot are listed in Table 1. 
2.3.6 Detection 
Detection was aided by horseradish peroxidase–conjugated secondary antibodies and 
using HRP-conjugated secondary antibodies and ECL reagents (Thermo, USA). Images were 
captured and analyzed by the Bio-Rad Gel Doc XR+ Imaging System (CA, USA).  
Some of the membranes were stripped and re-incubated with diverse antibodies. Stripping helped 
remove bound primary and secondary antibodies from a membrane.  
 
Antibody Species Source Catalog # Application/dilution 
CD63 Mouse DSHB Unversity of lowa H5C6 (1:500) 
GRP78 Rabbit Santa Cruz Sc-1368 (1:500) 
β -actin(JLA20) Mouse DSHB Unversity of lowa JLA20 (1:500) 
1. The antibodies of western blot. 
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2.4 RT-PCR Analysis 
2.4.1 Total RNA Extraction  
Total RNA was isolated From CCA exosome using TRIzol reagent (QIAGEN, Inc, 
Valencia, CA) and first stander of complementary DNA (cDNA) was reverse transcribed using 
the High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA). In brief, 700 μL 
of TRIzol™ Reagent was added directly to the culture dish to lyse the cells. Samples were 
incubated for 5 min at RT to allow complete separation of the nucleoproteins complex. 
Chloroform was then added, and the mixture was incubated for 15 min, then centrifuged for 15 
min at 12,000 × g at 4°C. Next, the aqueous phase, which contains the RNA, was transferred to a 
new tube. Isopropanol was added, incubated for 10 minutes and centrifuged for 10 minutes at 
12,000 × g at 4°C. The pellet was resuspended in 75% ethanol, then centrifuged for 5 minutes at 
7500 × g at 4°C. Finally, the pellet was allowed to air dry for 5 min then resuspended with 
RNase-free water. The extracted total RNA was stored at -80°C for further use.  
2.4.2 RT-PCR Analysis  
RNA extraction was quantified using Nano Drop 2000 (Thermo Scientific, Willington, 
DE) and reverse transcribed into first-strand cDNA and was run on a thermo cycler (Bio-Rad 
CFX ConnectTM, Hercules, CA). The amplified reaction products were visualized by running 
them on DNA Gels for 15 minutes.  
The mRNA levels of the targeted genes were detected by real-time PCR using iQTM 
SYBR Green Supermix reagents (Bio-Rad, Hercules, CA) and normalized using HPRT1or β-
Actin as an internal control. The primer sequences of real-time PCR are listed in Table 2.  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Gene Species Accession# Forward primer (5' to 3') 
 
Reverse primer (5' to 3') 
 
S1PR1 Rat NM_017301 CTCCGACTATGGCAACTATG GCTAACAGGTCCGAGAGG 
S1PR2 Rat NM_017192 GGAACACTACAATTACACCAAG GCGATTAGCACCAGAAGG 
S1PR3 Rat XM_225216 GGAGGGCAGTATGTTCGTAG GGGCAAGATGGTAGAGCAG 
SCT Rat NM_022670 AGCGAGGAGGACACAGAA ACCACAGCAAGCAGAGTT 
SCTR Rat NM_031115 TCCGAAGTTCCTCCTGAT TCTGACCATCCATCTTGTG 
SDF-1 Rat NM_022177 ATGTCGCCAGAGCCAACG CCACTTTAATTTCGGGTCAATGC 
POSTN Rat NM_001108550 AGAATGGAAGGGATGAAAG GCGAAGTATGTGTAGGAC 
TGF-β1 Rat X52498 GAGAAGAACTGCTGTGTA GGTTGTGTTGGTTGTAGA 
PDGFRb Rat NM_031525 CTAATGAGACTGACAATGACT AGGAGATGGTGGAAGAAG 
α -SMA Rat NM_031004 GAGTGATGGTTGGAATGG TCGTTATAGAAGGAGTGGT 
HPRT1 Rat NM_012583 CCAGCGTCGTGATTAGTG GCCTCCCATCTCCTTCAT 
β -Actin Rat NM_031144 TATCGGCAATGAGCGGTTCC AGCACTGTGTTGGCATAGAGG 
 
 
2.5 3-D Organic culturing. 
 
BDEsp-TDFE4 at an Initial plating density of 4 × 10
5 cells and BDEsp-TDEH10 at an Initial 
plating density 8 × 105 were mixed together with an appropriate volume of rat tail type I collagen 
gel matrix (BD Biosciences) and plate in six-well culture plates. The mixture was incubated at 
37C for 1 hour. Gel matrix was removed to 60-mm plate and culture overnight. After 24 hours 
fresh medium contains either exo-TCA, exo-DCA or exo-S1P were add to the culture. The 
culture medium was replaced at every 48 hours intervals. Finally, the gels were fixed 
immediately in 10% buffered formalin, embedded, sectioned and stained with hematoxylin and 
eosin. 
2.6 Statistical Analysis. 
 
All the results were got from at least three experiments. The results are reported as mean 
standard deviation. The one-way analysis of variance (ANOVA) was used to analyze the data. 
Statistical analysis was performed using GraphPad Prism 8.0 (GraphPad Soft Inc., San Diego, 
CA). The Value of Significance was set at P< 0.05.  
2. The primer sequences of real-time PCR 
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3  Chapter 3: Result 
3.1 Purification and Characterization of Exosomes Derived from Different CCA Cell 
Lines. 
Based on exosomes’ distinctive size and density, exosomes were extracted and purified 
from the CCA cell line (BDEsp-TDEH10). Next, transmission electron microscopy (TEM) and 
western blot analysis were used to characterize exosome isolation and purification. TEM analysis 
shows that the BDE-TDE exosomes had a distinctive saucer-shape structure that is surrounded 
by a lipid bilayer, and the TDE‐released exosomes ranged from 50 to 150 nm in diameter, as 
shown in Fig. 6A 
The Western blotting analysis further proved that the purified exosomes express CD63, the 
common marker of exosomes (Fig. 6B). Further, to confirm the purification of the exosome 
isolate, the GRP78 (ER marker) was examined. The data show (in Fig. 6B) the absence of 
GRP78 in the exosome samples in all cell lines’ media. 
Furthermore, Dynamic Light Scattering (DLS) analysis shows that the size of the BDEsp-
TDEH10-released exosomes is around 100 nm in diameter. Interestingly, TCA (but not the other 
bile acid) slightly increased the number of exosomes (Fig. 6C). 
Overall, DLS data and the Western blot data indicated that the vesicles released by CCA 
cells line are exosomes. Indeed, our extraction method, which involved successive centrifugation 
steps, yields purified exosomes free from cell debris. 
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3.2 BDEsp-TDEH10 CCA Exosomes Affect BDEsp-TDFE4 CAFs and Promote Their 
Secretory Factor Production. 
Exosomes are cell-derived vesicles that can act as essential intercellular communicators 
in the local tumor microenvironment54. Given that CAFs participate in tumor proliferation and 
invasion, we asked whether BDEsp-TDEH10-derived exosomes might have an effect on the CAF. 
To analyze whether the proliferation of CAFs was affected by CCA cancer-derived exosomes, a 
Cancer-associated myofibroblasts (BDEsp-TDFE4) was cultured in DMEM containing BDEsp-
TDEH10 cell-derived exosomes in the presence or absence of S1P (1 mg/mL) for 24 hours.  
Using quantitative reverse-transcriptase PCR (qRT-PCR) analysis we confirmed the 
elevated expression of α-Smooth muscle actin (α-SMA) mRNA in BDEsp-TDFE4 that was 
treated with BDEsp-TDEH10 cancer-cell-derived exosomes treated with S1P (Fig. 7A). 
Moreover, a stromal cell-derived factor 1-alpha (SDF-1), a chemokine that plays an important 
role in the invasion and migration of CCA cells55.A qRT-PCR was used to determine the mRNA 
expression levels of SDF-1 in the absence or presence of S1P BDEsp-TDEH10 cancer- cell-
derived exosomes. Interestingly, the purified exosomes from BDEsp-TDEH10 treated with S1P 
slightly increased the SDF-1 expression in BDEsp-TDFE4 (Fig. 7B). Data showed that, compared 
with the untreated group, treatment with S1P cancer exosomes resulted in slight increases in 
SDF-1. These results indicate that CCA-derived exosomes play a role in regulating genes 
involved in invasion and migration. 
Numerous factors produced by activated Cancer-associated myofibroblasts can 
considerably influence the CCA growth55. We studied whether the CCA exosome affects the 
production of these factors. A real-time RT-PCR was used to determine the mRNA expression 
levels of Transforming growth factor beta 1 (TGF- β) and Platelet-deriving growth factor 
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(PDGF) in the absence or presence of S1P BDEsp-TDEH10 cancer- cell-derived exosomes. Data 
showed that there is no significant increase in the expression in the TGF- β and PDGF in the 
BDEsp-TDFE4 that treated with S1P cancer exosomes (Fig. 7C, 7D). 
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3.3 Effect of CCA‐Derived Exosomes on Periostin Expression 
Periostin is a matricellular protein. The overexpression of the periostin gene was found in 
different types of human cancer 56 which could play a crucial role in the progression and 
metastasization of cancer. Furthermore, it has been reported that in human and rat 
cholangiocarcinoma, the CCA-derived fibroblasts positive for α-SMA are the exclusive origin of 
POSTN that is released in the desmoplastic stroma57 
To determine the role of exosome on the POSTN expression, exosomes were first 
purified from the conditioned media of BDEsp-TDEH10 treated with S1P (100 nM) for 48 
hours. Then, a cancer-associated myofibroblasts (BDEsp-TDFE4) was cultured in a medium 
containing PBS or a BDEsp-TDEH10 derived exosome (1mg/ml) for 24 hours. The results 
revealed that the periostin mRNA level in the cancer-associated myofibroblasts (BDEsp-
TDFE4) treated with BDEsp-TDEH10-derived exosomes that were treated with S1P were higher 
in comparison with those in cells treated with BDEsp-TDEH10-derived exosomes that were 
treated with PBS, according to the RT-qPCR data (Fig. 8B). These results suggest a potential 
link between periostin expression and cholangiocarcinoma-derived exosomes treated with S1P.  
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3.4 CCA-Released Exosomes and BDEsp-TDFE4 CAFs Induce BDEsp-TDEH10 CCA 
Cell Growth in Co-Culture 
After we showed that BDEsp-TDEH10-cell-derived exosomes affect the BDEsp-
TDFE4 CAFs, we set out to examine whether cancer-derived exosomes can stimulate the BDEsp-
TDEH10 growth in the co-culture. We used a 3-D co-culture model of organotypic CCA growth 
to examine this postulation. BDEsp-TDEH10 CCA cells were cultured with BDEsp-TDFE4 in a rat 
type 1 collagen-gel matrix that forms into 3-D duct-like structures, and a fresh medium with 
0.10% FBS containing either BDEsp-TDEH10-released exosome treated with TCA (100 μM), 
DCA (50 μM) or S1P (100 nM) were added to the cultures. Subsequently, the medium was 
changed every 48 hours for an eight-day treatment. These results show that BDEsp-TDEH10‐
derived exosomes that were treated with TCA and S1P significantly increased the number of 
CCA cell spheroid/duct-like structures when rat BDEsp-TDEH10 CCA cells were co-cultured 
with BDEsp-TDFE4 in the collagen-gel matrix (Figs. 9A, B). The result of the 3-D co-culture 
model of organotypic CCA growth revealed that CCA-derived exosomes treated with TCA or 
S1P significantly increased CCA growth. 
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3.5 Sphingosine 1-Phosphate Increase the Release of Exosomal S1PR2. 
 
Sphingosine 1-phosphate (S1P) is a bioactive lipid that is formed by the sphingosine 
kinase phosphorylation and binds to a family of five S1P-specific G protein coupled receptors 
(S1P1-5) that can be expressed in wide variety of tissues 
58. Our previous study found that CBA 
prompted progression and invasion of CCA by the activation of both ERK1/2 and Akt signaling 
59. In addition, it has been reported that breast cancer cells exosomes contain S1PR2 60.  
Therefore, we considered the possibility that S1P receptors could be released in the exosome 
from CCA cells.  
To determine the effect of conjugated bile acid and S1P on exosomes produced by CCA 
cells, BDEsp-TDEH10 treated with TCA, DCA and S1P for 48 hours. Then, qRT-PCR was used 
to determine the mRNA expression of the receptors in the CCA cell line. As shown in Fig. 10, 
S1P significantly increased S1PR2 levels in exosomes but not S1PR1 and S1PR3 (Fig.10).  This 
was of interest because our lab has previously demonstrated that S1PR2 is the most prevalent 
sphingosine 1-phosphate receptors in cholangiocarcinoma cells 59. 
Moreover, the secretin receptor (SCTR) is another receptor that might play a role in the 
CCA growth. SCTR is a G protein-coupled receptor 61. SCTR has been found to be highly 
expressed in cholangiocarcinoma 62,63. We therefore considered the possibility that SCTR could 
shed in the exosome from CCA cell line. 
BDEsp-TDEH10 cells were treated with TCA, DCA and S1P for 48 hours, and culture 
media were harvested for exosome isolation. The mRNA expression levels of SCT and SCTR 
were detected by real-time RT-PCR. From the results, it is clear that S1P had no significant 
effect on the SCT and SCTR levels in the cholangiocarcinoma-released exosome (Fig.11). 
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Figure 6. Purification and Characterization of Exosomes. BDEsp-TDEH10 cells were plated 
with exosome‐free DMEM medium and then treated with control, TCA (100 μM), DCA (50 
μM), or S1P (100 nM), for 48 hours. (A) Exosome isolated from BDE-TDE medium imaged by  
TEM. (B) Western blotting analysis of protein composition of exosomes. Protein expression 
levels of exosomal surface markers CD63 and GRP78 were determined by immunoblotting 
analysis in isolated exosomes from BDEsp-TDEH10 cell‐culture medium and total cell lysates. 
(C) DLS measurements of exosomes’ size distribution and number released from BDEsp-
TDEH10 cells.  
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Figure 6Purification and Characterization of Exosomes 
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Figure 7. Cancer-derived exosomes induce CAF markers’ expression. (A) Relative α-SMA 
mRNA expression levels in BDEsp-TDFE4 treated with  S1P exosomes isolated from BDEsp-
TDEH10 . (B) Relative SDF-1 mRNA expression levels in BDEsp-TDFE4 derived exosomes were 
determined by real‐time RT‐PCR and normalized using HPRT1 as an internal control. (C) 
Relative TGF- β mRNA expression levels in BDEsp-TDFE4 in the presence or absence of tumor 
exosome. (D) mRNA levels of PDGF were determined by real‐time RT‐PCR and normalized to 
HPRT1 as an internal control. 
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Figure 7Cancer-derived exosomes induce CAF markers’ expression. 
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Figure 8. Effect of exosome on POSTN expression in cholangiocarcinoma. BDEsp-
TDFE4 cells were treated with CCA exosome for 24 hours. mRNA levels of POSTN were 
determined by real‐time RT‐PCR and normalized to HPRT1 as an internal control. 
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Figure 8. Effect of exosome on POSTN expression in cholangiocarcinoma 
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Figure 9. Effect of BDEsp-TDEH10 exosome on the growth of spheroid structures 
formed in three-dimensional organotypic culture of BDEsp-TDEH10 and BDEsp-
TDFE4 cells. Cells were treated with BDEsp-TDEH10 exosome pretreated with or without 
TCA (100 μM), DCA (50 μM), or S1P (100 nM) for eight days. (A) Representative images 
of H&E staining of duct-like structures formed in vehicle control versus exosome treatment 
groups with TCA, DCA or S1P (B) The mean number of spheroid/duct-like structures/cm2. 
**P < 0.01; ****P < 0.001, compared to control group. 
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Figure 9Effect of BDEsp-TDEH10 exosome on the growth of spheroid structures formed in 
three-dimensional organotypic culture of BDEsp-TDEH10 and BDEsp-TDFE4 cells. 
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Figure 10. Differential expression of S1PRs in CCA exosome. Total RNA exosome was 
isolated from a rat BDEsp-TDEH10 cell, that was pretreated with TCA (100 μM), DCA (50 
μM), or S1P (100 nM), for 48 hours. mRNA levels of S1PRs were determined by real-time RT-
PCR (A) S1PR1. (B) S1PR2. (C) S1PR3 and normalized using β-Actin as an internal control. 
**P < 0.01 compared to control group. 
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Figure 10Differential expression of S1PRs in CCA exosome 
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Figure11. Expression of SCT and SCTR in CCA exosome.  Relative (A) SCT and (B) 
SCTR mRNA levels in isolated exosomes were determined by real‐time RT‐PCR and 
normalized using β-Actin as an internal control. 
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Figure 11Expression of SCT and SCTR in CCA exosome 
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4 Discussion 
 
 
In recent years, there has been growing interest in the role of the exosome in the tumor 
microenvironment. A growing body of literature has shown that tumor-derived exosomes 
considerably influence the cancer-associated myofibroblasts 64–67. Therefore, tumor-derived 
exosomes can alter the microenvironment to be more hospitable for the tumor. This study 
examined whether exosomes released by CCA cancer cells were involved in modulating cancer-
associated myofibroblasts and increase CCA growth. 
An exosome can be extracted by different methods. However, the major challenge for 
studying the cancer-derived exosome among these methods is to prevent intracellular 
microvesicles contaminants. In this study, we used differential ultracentrifugation as an isolation 
method. To validate the purity of isolated CCA-derived exosomes, we examined the presence of 
the exosome marker, the CD63 protein, and the ER marker (GRP78); which should not be 
present in exosomes. Our data show that CD63 was detected in the CCA-derived exosome 
extracts, while GRP78 was not present in the in the exosome samples. Furthermore, the result of 
the DLS analysis proves that the exosome size is approximately 100 nm in diameter, which 
agreed with the sizes previously reported 68. The presence of CD63 and the lack of GRP78 in the 
samples, and the appropriate size of the exosome strongly suggest that our method is effective at 
separating CCA-derived exosome from another cellular component. This method can be used in 
future studies on CCA- derived exosome influence on the microenvironment. 
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Cancer-associated myofibroblasts s (CAF) behavior is altered to significantly modify the 
tumor microenvironment, leading the promotion of tumor growth, progression, and metastasis 69. 
Moreover; tumors can use exosome to influence myofibroblasts behavior, making exosomes an 
important player in the intracellular communication in the tumor microenvironment. However, 
there are few studies that show exosomes potentially influence on the CAF. To determine 
whether CCA-derived exosomes can alter CAF cells’ production of pro-malignant factors, we 
used BDEsp-TDFE4 as a model.  CCA cells were treated with S1P and their exosomes isolated, 
these exosomes were used to treat BDEsp-TDFE4 leading to an increased expression of α-SMA 
mRNA; suggesting CCA-derived exosomes cause an increase in myofibroblasts cell’s 
proliferation and growth advancing the progression of the tumor microenvironment. Moreover, 
these BDEsp-TDFE4 cells also had an increase in SDF-1 mRNA levels. This is significant 
because SDF-1 is a soluble growth factor that is secreted by CAFs and it plays an important role 
in CCA invasion 70. Most importantly we determined that CCA-derived exosome treatment of 
BDEsp-TDFE4 significantly increase the expression of periostin (Fig. 7). It has been reported that 
periostin is involved in cholangiocarcinoma invasion 71.  Taken together, this data suggests that 
CCA-derived exosomes induce pro-malignant traits in myofibroblasts, progressing the tumor 
microenvironment by increasing the myofibroblasts production of soluble growth factors that 
promote tumor growth and increase metastasis. However, underlying mechanisms still need to be 
examined in future studies. 
The majority of the data was based on an in vitro culture system. In order to further study 
the interaction between CCA-derived exosome and CAF, a 3D organotypic CCA co-culture 
model was employed to mimics the vivo microenvironment. CCA cells were treated with TCA 
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or S1P, the resulting exosomes produced were used to treat the 3D organotypic model, 
significantly increased the number of spheroid/duct-like in the 3D structures. This data suggests 
that exposure to tumor exosome increase CCA cells growth. 
A number of studies have found that S1P could influence the tumor microenvironment by 
regulating CAF. For instance, Previous studies demonstrated that SPHK1/S1P can control 
communication between melanoma cancer cells and CAF 72. Recently, Ashref et al. (2018) 
have reported that breast-released exosome contains S1PR2 that are internalized by 
myofibroblasts, leading to the increased activation of the S1PR2 pathway associated with growth 
in the myofibroblasts. 60. In the present study, we further examined the presence of S1PR in the 
CCA-released exosome. RT-qPCR was used to determine the mRNA expression of S1PR1, 
S1PR2, and S1PR3 in the exosomes. It was found that treating CCA with S1P significantly 
increased the S1PR2 mRNA levels in the released exosomes (Fig. 9). Nonetheless, our limited 
finding suggests that CCA-derived exosomal-S1PR2 might increase the growth factors level in 
the myofibroblasts leading the progression of the tumor microenvironment. The question remains 
how CAF internalized the CCA-released exosomal S1PR2. 
In conclusion, we have found that CCA-derived exosomes can induce pro-malignant 
traits of CAF cells. This is primarily due to the increase of growth factor production in CAF cells 
that have been exposed to CCA-derived exosomes, leading to an increase in tumor growth and 
metastasis. Equally importantly, the exposing CCA with bile acids and S1P, known promoters of 
CCA development, leads to the production of CCA-derived exosomes that are more capable of 
inducing pro-malignant traits in CAF. CCA-derived exosomes could be the missing link between 
how bile acid build-up in the bile duct results in the alters behavior of myofibroblasts while in 
the presence of CCA.  
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